Optimal follow-up intervals for different stages of chronic kidney disease: a prospective observational study

[1] Jha V(2013)Chronic kidney disease: global dimension and perspectives Lancet 382 260-272

[2] Garcia-Garcia G(2004)Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 1296-1305

[3] Iseki K(2004)Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies J Am Soc Nephrol 15 1307-1315

[4] Li Z(2003)National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 137-147

[5] Naicker S(2007)Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from kidney disease improving global outcomes Kidney Int 72 247-259

[6] Plattner B(2014)Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality JAMA 311 2518-2531

[7] Saran R(2012)[Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012] Nihon Jinzo Gakkai Shi 54 1034-1191

[8] Wang AY(2014)GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 64 821-835

[9] Yang CW(2012)Bone-density testing interval and transition to osteoporosis in older women N Engl J Med 366 225-233

[10] Go AS(2013)Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians Ann Intern Med 159 835-847

[1] Jha V(2013)Chronic kidney disease: global dimension and perspectives Lancet 382 260-272

[2] Garcia-Garcia G(2004)Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 1296-1305

[3] Iseki K(2004)Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies J Am Soc Nephrol 15 1307-1315

[4] Li Z(2003)National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 137-147

[5] Naicker S(2007)Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from kidney disease improving global outcomes Kidney Int 72 247-259

[6] Plattner B(2014)Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality JAMA 311 2518-2531

[7] Saran R(2012)[Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012] Nihon Jinzo Gakkai Shi 54 1034-1191

[8] Wang AY(2014)GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 64 821-835

[9] Yang CW(2012)Bone-density testing interval and transition to osteoporosis in older women N Engl J Med 366 225-233

[10] Go AS(2013)Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians Ann Intern Med 159 835-847